Elevated levels of Ang-(1-9) have been associated with improved outcomes in myocardial infarction and hypertension, notably after the administration of angiotensin-converting enzyme (ACE) inhibitors or AT1R blockers (1, 2, 10–13), highlighting its potential therapeutic value in cardiovascular disease management. This evidence concerns the gene ACE and myocardial infarction.